Introduction
Malaria is one of the most widespread diseases in the world. According to WHO estimates 40% of the world's populations presently live under malarial threat [1] .
Around 300 and 500 million cases of malaria occur annually, leading to 1-3 million deaths [1] . Its control is globally a high priority task. Although effective antimalarial agents have been known for a long time, the alarming spread of drug resistant strains of Plasmodium falciparum, which is the most lethal parasite species, undergoes the urgency and continuous need for the discovery of new therapeutics. A major initiative in this direction is to find enzyme targets that are critical to the disease process or essential for the survival of the parasite. Identification and design of novel chemical entities specifically affecting these targets could lead to better drugs for the treatment of malaria [2] .
Pyrimethamine, trimethoprim and cycloguanil inhibit malarial dihydrofolate reductase (DHFR), one of the few welldefined, validated targets in malarial chemotherapy [3] . These antimalarials inhibit DHFR by competing with the natural substrate dihydrofolic acid. Unfortunately, point mutations at certain amino acid residues surrounding the P. falciparum DHFR active site have resulted in resistance, compromising the clinical effectiveness of pyrimethamine and cycloguanil [4, 5] .
Despite this, the folate pathway remains a good target for malarial chemotherapy because the enzyme is limited in its mutational capability, owing to loss in enzyme function [6] [7] [8] . Pritam N. Dube et.al. 3 between the 1,2-dihydro- 1,3,5-triazine-4,6- diamine heterocycle and the substituted phenyl ring [9] . So, rather than identifying new molecules for efficacy, modified 1,2-dihydro-1,3,5-triazine-4,6-diamine heterocycle having many advantages and efficiency are now in priority for antimalarial chemotherapy.
Experimental

Data set
A data set of 28 compounds of side chain modified 1,2-dihydro-1,3,5-triazine-4,6-diamine heterocycle for antimalarial activities against pyrimethamine and cycloguanil sensitive and resistant (FCR-3) P. falciparum strains was used for the present 2D QSAR study [10] . There is high structural diversity and a sufficient range of the biological activity in the selected series of these derivatives ( The manual data selection method [12] [13] [14] [15] was adopted for division of training and test data set comprising of 21 and 7 molecules, respectively. Seven compounds, namely 1.1- building QSAR models and can explain the situation more effectively [14] [15] [16] .
In the selected equations, the crosscorrelation limit was set at 0.5, the number of variables at 10, and the term selection criteria at r 2 . An F value was specified to evaluate the significance of a variable. The variance cutoff was set at 0, with auto scaling in which the number of random iterations was set at 100. In SW forwardbackward variable selection algorithm, the model is repeatedly altered from the previous one by adding or removing a predictor variable in accordance with the 
Model quality and validation
The developed QSAR models are evaluated using the following statistical measures: n, (the number of compounds in regression); k, where yi, and ŷi are the actual and predicted activity of the i th molecule in the test set, respectively, and ymean is the average activity of all molecules in the training set.
Results and discussion
The QSAR study of 28 new side chain modified 1,2-dihydro-1,3,5-triazine-4,6-diamine heterocycle derivatives for antimalarial activities (Table 1) were selected by manual selection method and the models were validated by both internal and external validation procedure.
To ensure a fair comparison, the same training and test sets were used for each model's development. A Uni-column statistics for training set and test set was generated to check correctness of selection criteria for trainings and test set molecules. Least Squares regression (PLR) were carried out to find out the factors responsible for the biological activity (Table 3) 
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